EASTONBIOPHARMACEUTICALS(SH:688513) Shang Hai Zheng Quan Bao·2025-10-27 22:39Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, and assumes legal responsibility for its content [1] - The quarterly financial report has not been audited [2] - The net profit attributable to shareholders increased by 2.77% year-on-year, while the net profit excluding non-recurring gains and losses grew by 4.69% year-on-year [2] Financial Data - The report period refers to the three months from the beginning to the end of the quarter [2] - The company recognized a total of 13.2962 million yuan in stock incentive expenses from the beginning of the year to the end of the reporting period [2] - The company’s repurchase account held 2,179,346 shares, accounting for 1.23% of the total share capital of 176,532,256 shares as of the end of the reporting period [5] Shareholder Information - There are no changes in the borrowing or returning of shares by the top ten shareholders due to transfer and financing [6] - The report does not include any additional important information regarding the company's operational situation during the reporting period [6]